Keros Therapeutics Inc. (KROS) Financial Statements (2024 and earlier)

Company Profile

Business Address 1050 WALTHAM STREET, SUITE 302
LEXINGTON, MA 02421
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments331,147279,048230,042265,876
Cash and cash equivalents331,147279,048230,042265,876
Receivables143 18,030172
Prepaid expense6381,037993785
Other current assets1,001180340160
Other undisclosed current assets14,3645,5022,035733
Total current assets:347,293285,767251,440267,726
Noncurrent Assets
Operating lease, right-of-use asset15,33415,5481,067878
Property, plant and equipment4,1342,0211,335724
Restricted cash and investments1,2121,3271,327115
Other noncurrent assets2,0522,11882 
Total noncurrent assets:22,73221,0143,8111,717
TOTAL ASSETS:370,025306,781255,251269,443
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities23,36816,09210,9846,761
Accounts payable5,4503,3393,6452,149
Accrued liabilities17,91812,7537,3394,612
Other undisclosed current liabilities1,005455862423
Total current liabilities:24,37316,54711,8467,184
Noncurrent Liabilities
Long-term debt and lease obligation:   231476
Liabilities, other than long-term debt13,43912,811 62
Other liabilities    62
Operating lease, liability13,43912,811231476
Other undisclosed noncurrent liabilities   (231) 
Total noncurrent liabilities:13,43912,811231538
Total liabilities:37,81229,35812,0777,722
Equity
Equity, attributable to parent332,213277,423243,174261,721
Common stock3222
Additional paid in capital713,636505,855366,927326,730
Accumulated deficit(381,426)(228,434)(123,755)(65,011)
Total equity:332,213277,423243,174261,721
TOTAL LIABILITIES AND EQUITY:370,025306,781255,251269,443

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenues14,755 20,100 
Net investment income14,755   
Gross profit:14,755 20,100 
Operating expenses(170,092)(114,790)(76,473)(46,657)
Other undisclosed operating loss(14,604)   
Operating loss:(169,941)(114,790)(56,373)(46,657)
Nonoperating income (expense)16,94910,111(360)1,124
Other nonoperating income (expense)(206)3,031(356)160
Interest and debt expense  (1)(4) 
Loss from continuing operations before equity method investments, income taxes:(152,992)(104,680)(56,737)(45,533)
Other undisclosed income from continuing operations before income taxes  14 
Loss from continuing operations before income taxes:(152,992)(104,679)(56,733)(45,533)
Income tax expense (benefit)   (2,011)172
Loss from continuing operations:(152,992)(104,679)(58,744)(45,361)
Loss before gain (loss) on sale of properties:(58,744)(45,361)
Net loss available to common stockholders, diluted:(152,992)(104,679)(58,744)(45,361)

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net loss:(152,992)(104,679)(58,744)(45,361)
Comprehensive loss, net of tax, attributable to parent:(152,992)(104,679)(58,744)(45,361)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: